Aspen Neuroscience
Aspen is dedicated to developing and delivering iPSC- derived autologous cell replacement therapies for patients with high unmet medical need, beginning with Parkinson’s disease (PD).
We aim to transform the lives of people living with PD with our personalized regenerative therapies that offer real hope where none existed before.
AWARDS
10835 Road to the Cure
Ste. 100
San Diego, CA 92121
Ste. 100
San Diego, CA 92121
NEWS
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
JOBS
IN THE PRESS